Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Low-Toxicity Anticancer Agent Proves Effective Against a Variety of Cancers

By BiotechDaily International staff writers
Posted on 08 Apr 2013
Researchers have discovered that the small chemical molecule FL118, a new formulation of a promising anticancer agent, is even more effective in controlling two kinds of cancer than an older version of the compound proved to be six months earlier. Further findings also suggest that the agent may successfully treat other solid tumors as well.

In their earlier research, a team led by Fengzhi Li, PhD, associate professor of oncology in Roswell Park Cancer Institute’s (RPCI; Buffalo, NY, USA) department of pharmacology and therapeutics, demonstrated that FL118 eliminated human colon and head-and-neck tumors in animal models without relapse but was limited in that it could be delivered only by intraperitoneal (IP) administration. This new study, to be published in the April 8, 2013, issue of the American Journal of Translational Research, compares the earlier formulation of the agent to a new version that can also be administered intravenously, adapting it to a much wider potential clinical application.

Comparing the antitumor effectiveness and therapeutic index, or relative toxicity, of FL118 in its new intravenous (IV) formulation with the earlier form, the researchers found that maximum tolerated dose increased three- to seven-fold, depending on dosing regimen. While the original formulation contained Tween 80 or polysorbate 80, a solvent typically included in drug formulations, the agent in its new composition is free of Tween 80, resulting in significantly lower toxicity.

FL118 is a targeted therapy that selectively inhibits the expression of four major cancer-survival gene products: survivin, XIAP, Mcl-1, and/or cIAP2. Whereas both studies assessed the compound’s effectiveness against models of head-and-neck and colon tumors, other research from Dr. Li’s lab suggests that mesothelioma, ovarian, and pancreatic cancers, and potentially other solid tumors, may also be good targets for treatment with FL118.

“This work represents a significant move forward,” noted Dr. Li, senior author on the study. “We’re targeting four of the most resilient and pervasive cancer survival mechanisms, and because the findings from preclinical testing have been so striking, we’re anxious to see FL118 tested in the clinical setting.”

The study’s findings were published online April 2, 2013, in the journal PLOS ONE.

Related Links:

Roswell Park Cancer Institute


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.